journal article·2016-07

Sequential culture on biomimetic nanoclay scaffolds forms three‐dimensional tumoroids

Kalpana S. Katti, MD Shahjahan Molla, Fataneh Karandish, Manas K. Haldar, Sanku Mallik, Dinesh R. Katti

Publisher page

Abstract

Abstract In recent times, the limitation of two‐dimensional cultures and complexity ofin vivomodels has paved the way for the development of three‐dimensional models for studying cancer. Here we report the development of a new tumor model using PCL/HAPClay scaffolds seeded with a sequential culture of human mesenchymal stem cells (hMSCs) followed by human prostate cancer cells (HPCCs). This nanocomposite system is used as a test‐bed for studying cancer metastasis and efficacy of anti‐cancer drugs using a polymersome delivery method. A novel sequential cell culture system in three‐dimensionalin vitrobone model provides a unique bone mimetic environment. The hMSCs seeded scaffolds are seeded with prostate cancer cells after the hMSCs have differentiated into osteoblasts. Sequential culture on the scaffolds has shown formation of tumoroids or microtissue consisting of organized, densely packed round cells with hypoxic core regions similar toin vivotumors. Such tumoroids are not observed on HPCC seeded scaffolds or when HPCCs sequentially cultured with human osteoblast cells. Clearly, the newly differentiated hMSCs play a vital role in the ability of cancer cells to grow into tumoroids and cause disease. The PCL/HAPclay scaffold system seeded with the sequential culture of hMSCs, and HPCCs presents a good model system for study of the interactions between prostate cancer cells and bone microenvironment. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1591–1602, 2016.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Bone Tissue Engineering Materials · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Civil and Environmental Engineering North Dakota State University Fargo North Dakota 58105

Department of Pharmaceutical Sciences North Dakota State University Fargo North Dakota 58105

Funding

National Science Foundation · University of Notre Dame

References (91)

Show source-provided references
1. 10.1016/j.jbiomech.2013.09.02910.1016/j.jbiomech.2013.09.029 ↗
2. 10.1089/ten.tea.2009.066810.1089/ten.tea.2009.0668 ↗
3. 10.1038/nrclinonc.2011.3410.1038/nrclinonc.2011.34 ↗
4. 10.1038/3509405910.1038/35094059 ↗
5. 10.1016/j.biomaterials.2011.04.07610.1016/j.biomaterials.2011.04.076 ↗
6. 10.1002/biot.20070022810.1002/biot.200700228 ↗
7. 10.1002/jps.2225710.1002/jps.22257 ↗
8. 10.1101/sqb.2005.70.01310.1101/sqb.2005.70.013 ↗
9. 10.1089/ten.2005.11.18210.1089/ten.2005.11.182 ↗
10. 10.1023/A:101459482550210.1023/A:1014594825502 ↗
11. 10.1007/s11095-010-0198-310.1007/s11095-010-0198-3 ↗
12. 10.1073/pnas.040574710210.1073/pnas.0405747102 ↗
13. 10.1023/B:JMSM.0000021108.74004.7e10.1023/B:JMSM.0000021108.74004.7e ↗
14. 10.1002/jcp.2032010.1002/jcp.20320 ↗
15. 10.1016/j.molonc.2007.02.00410.1016/j.molonc.2007.02.004 ↗
16. 10.1152/ajpcell.00196.200410.1152/ajpcell.00196.2004 ↗
17. 10.1007/s10585-008-9190-210.1007/s10585-008-9190-2 ↗
18. 10.1002/adfm.20130031210.1002/adfm.201300312 ↗
19. 10.1158/0008-5472.CAN-13-099110.1158/0008-5472.CAN-13-0991 ↗
20. 10.1038/nmeth108510.1038/nmeth1085 ↗
21. 10.1016/j.biomaterials.2010.01.11810.1016/j.biomaterials.2010.01.118 ↗
22. 10.1038/nrc307810.1038/nrc3078 ↗
23. 10.3390/jfb601008110.3390/jfb6010081 ↗
24. 10.1002/term.26810.1002/term.268 ↗
25. 10.1016/j.biomaterials.2010.03.01710.1016/j.biomaterials.2010.03.017 ↗
26. 10.1016/j.biomaterials.2011.03.05510.1016/j.biomaterials.2011.03.055 ↗
27. 10.1016/j.biomaterials.2012.06.01210.1016/j.biomaterials.2012.06.012 ↗
28. 10.1016/j.biomaterials.2011.07.00110.1016/j.biomaterials.2011.07.001 ↗
29. 10.1016/j.bone.2014.02.00110.1016/j.bone.2014.02.001 ↗
30. 10.1016/j.biomaterials.2013.11.05010.1016/j.biomaterials.2013.11.050 ↗
31. 10.1016/j.biomaterials.2015.01.07610.1016/j.biomaterials.2015.01.076 ↗
32. 10.1021/am506094c10.1021/am506094c ↗
33. 10.1089/ten.teb.2013.078210.1089/ten.teb.2013.0782 ↗
34. 10.1016/j.actbio.2014.12.00810.1016/j.actbio.2014.12.008 ↗
35. 10.2119/molmed.2010.0015710.2119/molmed.2010.00157 ↗
36. 10.1038/cr.2008.4010.1038/cr.2008.40 ↗
37. 10.2106/00004623-199404000-0001310.2106/00004623-199404000-00013 ↗
38. 10.1097/00003086-198903000-0003510.1097/00003086-198903000-00035 ↗
39. 10.1242/jcs.102.2.34110.1242/jcs.102.2.341 ↗
40. 10.1089/ten.1995.1.32710.1089/ten.1995.1.327 ↗
41. 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F ↗
42. 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I ↗
43. 10.1098/rsta.2010.000810.1098/rsta.2010.0008 ↗
44. 10.1002/jbm.a.3456110.1002/jbm.a.34561 ↗
45. 10.1002/jbm.a.3534210.1002/jbm.a.35342 ↗
46. 10.1073/pnas.120891610910.1073/pnas.1208916109 ↗
47. Vesicular delivery of crystalline calcium minerals to ECM in biomineralized nanoclay composites
48. 10.1016/j.jsb.2011.03.01410.1016/j.jsb.2011.03.014 ↗
49. 10.1002/jbm.a.3534210.1002/jbm.a.35342 ↗
50. 10.1007/s11837-015-1361-410.1007/s11837-015-1361-4 ↗
51. 10.1002/adma.20110463110.1002/adma.201104631 ↗
52. 10.1073/pnas.122140311010.1073/pnas.1221403110 ↗
53. 10.1016/j.coche.2013.12.00810.1016/j.coche.2013.12.008 ↗
54. 10.1016/j.msec.2011.03.00110.1016/j.msec.2011.03.001 ↗
55. 10.1098/rsta.2010.001310.1098/rsta.2010.0013 ↗
56. 10.1016/j.actbio.2010.10.02810.1016/j.actbio.2010.10.028 ↗
57. 10.1016/j.biomaterials.2014.04.02610.1016/j.biomaterials.2014.04.026 ↗
58. 10.1517/14796694.1.1.710.1517/14796694.1.1.7 ↗
59. 10.1007/s11095-013-1290-210.1007/s11095-013-1290-2 ↗
60. 10.1021/mp500037310.1021/mp5000373 ↗
61. 10.1002/jbm.a.3456110.1002/jbm.a.34561 ↗
62. 10.1115/1.400214910.1115/1.4002149 ↗
63. 10.1021/bm050321910.1021/bm0503219 ↗
64. 10.1371/journal.pone.012564110.1371/journal.pone.0125641 ↗
65. 10.1002/pros.2123110.1002/pros.21231 ↗
66. 10.1016/j.jconrel.2011.10.00510.1016/j.jconrel.2011.10.005 ↗
67. 10.1016/0005-2736(90)90091-210.1016/0005-2736(90)90091-2 ↗
68. 10.1038/nrc152810.1038/nrc1528 ↗
69. Therapeutic implications of enhanced G0/G1 checkpoint control induced by coculture of prostate cancer cells with osteoblasts
70. Implication of cell kinetic changes during the progression of human prostatic cancer
71. 10.1016/S0090-4295(98)00182-410.1016/S0090-4295(98)00182-4 ↗
72. 10.1038/sj.bjc.660011510.1038/sj.bjc.6600115 ↗
73. 10.1097/00041552-199707000-0000210.1097/00041552-199707000-00002 ↗
74. 10.1074/jbc.M40984620010.1074/jbc.M409846200 ↗
75. 10.1371/journal.pone.001679810.1371/journal.pone.0016798 ↗
76. 10.1289/ehp.898011710.1289/ehp.8980117 ↗
77. 10.1016/0047-6374(81)90035-X10.1016/0047-6374(81)90035-X ↗
78. 10.1016/0169-6009(90)90109-S10.1016/0169-6009(90)90109-S ↗
79. Effect of dynamic 3‐D culture on proliferation, distribution, and osteogenic differentiation of human mesenchymal stem cells10.1002/jbm.a.31967 ↗
80. 10.1089/ten.tea.2009.058310.1089/ten.tea.2009.0583 ↗
81. Prostate cancer cells induce osteoblast differentiation through a Cbfa1‐dependent pathway
82. 10.1177/1045441192003003050110.1177/10454411920030030501 ↗
83. 10.4161/org.6.3.1204110.4161/org.6.3.12041 ↗
84. 10.1371/journal.pone.007534510.1371/journal.pone.0075345 ↗
85. 10.1038/onc.2013.23310.1038/onc.2013.233 ↗
86. 10.1002/(SICI)1097-4636(199707)36:1<17::AID-JBM3>3.0.CO;2-O10.1002/(SICI)1097-4636(199707)36:1<17::AID-JBM3>3.0.CO;2-O ↗
87. Engineering of bone tissue with porcine bone marrow stem cells in three‐dimensional trabecular metal: in vitro and in vivo studies
88. 10.1002/jcb.1066110.1002/jcb.10661 ↗
89. 10.1002/pros.2106510.1002/pros.21065 ↗
90. 10.1016/S0169-409X(02)00179-510.1016/S0169-409X(02)00179-5 ↗
91. 10.2174/157016305486688210.2174/1570163054866882 ↗